- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
LayerBio granted patent for novel drug delivery platform
The novel sustained-release technology has potential to eliminate the need for eye drops after cataract surgery.
LayerBio Inc. announced this week it has received a patent for its OcuRing drug delivery platform.
According to Kenneth Mandell, MD, PhD, CEO and founder of LayerBio, the patent issuance marks a key milestone for the drug delivery platform, which is a novel bioerodible sustained-release technology for use with any standard IOL in cataract surgery.
“LayerBio will continue to develop our portfolio of patents for the OcuRing platform in order to produce safer, more effective and better-tolerated alternatives to topical eye drops for patients undergoing cataract surgery,” he said in a statement.
According to the company, the patent provides coverage for a variety of drug product compositions, methods of use, and delivery systems for LayerBio's propriety bioerodible drug delivery rings that release therapeutic medications for use in cataract surgery.
"OcuRing has the potential to transform the standard of care for cataract surgery," said Richard Lindstrom, MD, a cataract surgeon and member of LayerBio's Board of Directors. "By automatically releasing medicine inside the eye after cataract surgery, OcuRing can ensure compliance, improve outcomes and enhance the overall patient experience."
LayerBio's lead product candidate OcuRing-K is a sustained-release nonsteroidal anti-inflammatory drug (NSAID) formulation of ketorolac, an opioid-sparing analgesic with proven efficacy for reducing inflammation and pain associated with cataract surgery.
"OcuRing-K is a game-changer because it provides all of the benefits of an NSAID without the ocular surface side effects," said Eric Donnenfeld, MD, chairman of LayerBio's medical advisory board. "By delivering ketorolac directly inside the eye, it maintains a therapeutic plateau and essentially eliminates the risks of surface corneal toxicity associated with NSAID eye drops."
In addition to NSAIDs, the OcuRing platform has the capacity to deliver other ophthalmic medications, including corticosteroids, antibiotics and glaucoma medications. LayerBio will continue to develop innovative products that address unmet medical needs for cataract surgery and other eye conditions.
